BLACANDIProject ID: 673077
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
BLACANDI can improve life quality and cut cost of diagnosing and managing bladder cancer in half
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Call for proposal:H2020-SMEINST-1-2014See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
The BLACANDI project aims to dramatically improve the diagnosis and management of bladder cancer patients by substituting a highly invasive and expensive test with a non-invasive and inexpensive test. Bladder cancer is the 6th most common cancer with an estimated 357,000 new cases worldwide every year, of which 180,000 are European. This type of cancer has the highest lifetime treatment costs per patient (pp) of all cancers. This high incidence, coupled with it’s relapsing nature, means that bladder cancer poses an enormous burden on health care systems. Current diagnostics and recurrence routine tests are performed through highly invasive and expensive procedures, such as cystoscopy.
The Danish SME Genomic Expression Aps has licensed a technology composed of a patented filtration device that enhances the selection of tumor cells in urine, and aims at the clinical validation of a new combination of biomarkers.
Our solution BLACANDI (Filtration Device in combination with selected biomarkers) is currently being tested in a small clinical trial in Denmark, in patients presenting with hematuria (blood in urine). Preliminary results indicate that the test can substitute cystoscopy identifying more than 90% of all bladder cancer patients.
Substituting routine cystoscopy with the BLACANDI system could cut the cost of diagnosis and managing bladder cancer in half. In Europe the cost of diagnosing bladder cancer is €1.8 billion/year, thus we could save €900 million.
Whereas the technology behind the filtration device and the selected biomarkers is already demonstrated, further maturation of the tests into fully commercial and operational solutions is hampered by the absence of a large clinical validation of the BLACANDI system.
Furthermore, there is a need to corroborate our business strategy, since it requires customization to different health care systems. This phase 1 feasibility study provides us that opportunity.
EU contribution: EUR 50 000
BORGSKRIVERVEJ 3 2 TH
2400 KOBENHAVN NV